Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084338 · ClinicalTrials.gov registry record · Phase 2
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
A Phase 2 study of Prostate Cancer, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT06084338 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 60 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06084338, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and cessation of castration, and then followed by testosterone replacement, is an effective treatment for metastatic castration resistant prostate cancer. All patients will be treated with stereotactic ablative radiotherapy and PSMA targeted radiopharmaceutical therapy with cessation of castration. Half of patients are randomized to either receive, or not receive, subsequent testosterone replacement.
Conditions Studied
Interventions
- RADIATION stereotactic ablative radiotherapy
- DRUG Pluvicto
- DRUG topical testosterone
Study Locations (4)
California
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA - West Los Angeles
Illinois
- Edward Hines Jr. VA Hospital, Hines, IL - Hines
Indiana
- Richard L. Roudebush VA Medical Center, Indianapolis, IN - Indianapolis
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06084338
The ClinicalTrials.gov registry entry for NCT06084338 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which stereotactic ablative radiotherapy is the first listed.
NCT06084338 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT06084338 about?
NCT06084338 is a clinical study titled "Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc". This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and cessation of castration, and then followed by testosterone re...
What is the current status of trial NCT06084338?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-12-14. Estimated completion is 2028-12-31.
What conditions does trial NCT06084338 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06084338?
The interventions under investigation include: stereotactic ablative radiotherapy (RADIATION), Pluvicto (DRUG), topical testosterone (DRUG).
Who is sponsoring clinical trial NCT06084338?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06084338 being conducted?
This trial has 4 study locations across California, Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.